Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial

Neurorehabilitation and Neural Repair

Volumn 31, Issue 7, 2017, Pages 638-647

  Savadi Oskouie, Daryoush ^a   Sharifipour, Ehsan ^b   Sadeghi Bazargani, Homayoun ^a   Hashemilar, Mazyar ^a   Nikanfar, Masoud ^a   Ghazanfari Amlashi, Saeed ^a   Abbaszade, Zahra ^a   Sadeghihokmabadi, Elyar ^a   Rikhtegar, Reza ^a   Golzari, Samad E J ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b QOM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

acute ischemic stroke; citalopram; functional outcome; randomized clinical trial; selective serotonin reuptake inhibitors; stroke rehabilitation

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CITALOPRAM; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIARRHEA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMOTIONAL DISORDER; EMOTIONAL FLATTENING; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; KAPLAN MEIER METHOD; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NAUSEA; PHYSIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; STROKE REHABILITATION; TREATMENT OUTCOME; XEROSTOMIA; CEREBROVASCULAR ACCIDENT; CONVALESCENCE; DRUG EFFECTS; MIDDLE AGED; MORTALITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CITALOPRAM; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; SEROTONIN UPTAKE INHIBITORS; STROKE; STROKE REHABILITATION; TREATMENT OUTCOME;

EID: 85024110395     PISSN: 15459683     EISSN: 15526844     Source Type: Journal    
DOI: 10.1177/1545968317704902     Document Type: Article

References (44)

1. Donnane GA, Fisher M, Davis SM., Stroke. Lancet. 2008; 10: 1612-1623.
2. Weimar C, Kurth T, Kraywinkel K, et al.Assessment of functioning and disability after ischemic stroke. Stroke. 2002; 33: 2053-2059.
3. Delbari A, Salman Roghani R, Tabatabaei SS, Rahgozar M, Lokk J., Stroke epidemiology and one-month fatality among an urban population in Iran. Int J Stroke. 2001; 6: 195-200.
4. Chollet F, Tardy J, Albucher JF, et al.Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011; 10: 123-130.
5. Burns JD, Green DM, Metivier K, DeFusco C., Intensive care management of acute ischemic stroke. Emerg Med Clin North Am. 2012; 30: 713-744.
6. Blinzler C, Breuer L, Huttner HB, Schellinger PD, Schwab S, Köhrmann M., Characteristics and outcome of patients with early complete neurological recovery after thrombolysis for acute ischemic stroke. Cerebrovasc Dis. 2011; 31: 185-190.
7. Pantoni L, Fierini F, Poggesi A., Thrombolysis in acute stroke patients with cerebral small vessel disease. Cerebrovasc Dis. 2014; 37: 5-13.
8. Paul CL, Ryan A, Rose S, et al.How can we improve stroke thrombolysis rates? A review of health system factors and approaches associated with thrombolysis administration rates in acute stroke care. Implement Sci. 2016; 11: 51.
9. Chollet F, Cramer SC, Stinear C, et al.Pharmacological therapies in post stroke recovery: recommendations for future clinical trials. J Neurol. 2014; 261: 1461-1468.
10. Budhdeo S, Rajapaksa S., Functional recovery in cerebral palsy may be potentiated by administration of selective serotonin reuptake inhibitors. Med Hypotheses. 2011; 77: 386-388.
11. Engelter ST., Safety in pharmacological enhancement of stroke rehabilitation. Eur J Phys Rehabil Med. 2013; 49: 261-267.
12. Chollet F., Pharmacologic approaches to cerebral aging and neuroplasticity: insights from the stroke model. Dialogues Clin Neurosci. 2013; 15: 67-76.
13. Gaillard R, Mir O., Fluoxetine and motor recovery after ischaemic stroke. Lancet Neurol. 2011; 10: 499; author reply 500-501.
14. Mead GE, Hsieh CF, Lee R, et al.Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012;(11): CD009286.
15. Zittel S, Weiller C, Liepert J., Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair. 2008; 22: 311-314.
16. Mikami K, Jorge RE, Adams HP Jr, et al.Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry. 2011; 19: 1007-1015.
17. Selim MH, Molina CA., Post-stroke treatment with selective serotonin reuptake inhibitors: a journey from sadness to motor recovery. Stroke. 2012; 43: 3154-3155.
18. Marshall RS., Should every patient with stroke be on selective serotonin reuptake inhibitors? No. Stroke. 2012; 43: 3152-3153.
19. Adams HP Jr, Bendixen BH, Kappelle LJ, et al.Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24: 35-41.
20. Wallis Sean A., Binomial confidence intervals and contingency tests: mathematical fundamentals and the evaluation of alternative methods. J Quant Linguistics. 2013; 20: 178-208.
21. Ofek K, Schoknecht K, Melamed-Book N, Heinemann U, Friedman A, Soreq H., Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO/muscarinic signalling. J Cell Mol Med. 2012; 16: 2736-2744.
22. Espinera AR, Ogle ME, Gu X, Wei L., Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. Neuroscience. 2013; 247: 1-11.
23. Sas K, Csete K, Vezekényi Z, Sztriha L, Vécseil L, Papp JG., Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits. Acta Physiol Hung. 2007; 94: 167-177.
24. Sonde L, Lokk J., Effects of amphetamine and/or l -dopa and physiotherapy after stroke: a blinded randomized study. Acta Neurol Scand. 2007; 115: 55-59.
25. Treig T, Werner C, Sachse M, Hesse S., No benefit from d -amphetamine when added to physiotherapy after stroke: a randomized, placebo-controlled study. Clin Rehabil. 2003; 17: 590-599.
26. Gladstone DJ, Danells CJ, Armesto A, et al.Subacute Therapy with Amphetamine and Rehabilitation for Stroke Study Investigators. Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial. Stroke. 2006; 37: 179-185.
27. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R., Amphetamine paired with physical therapy accelerates motor recovery after stroke: further evidence. Stroke. 1995; 26: 2254-2259.
28. Engelter ST, Urscheler N, Baronti F, et al.Frequency and determinants of using pharmacological enhancement in the clinical practice of in-hospital stroke rehabilitation. Eur Neurol. 2012; 68: 28-33.
29. Dam M, Tonin P, De Boni A, et al.Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996; 27: 1211-1214.
30. Pariente J, Loubinoux I, Carel C, et al.Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001; 50: 718-729.
31. Loubinoux I, Pariente J, Boulanouar K, et al.A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. Neuroimage. 2002; 15: 26-36.
32. Acler M, Robol E, Fiaschi A, Manganotti P., A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol. 2009; 256: 1152-1158.
33. Berends HI, Nijlant J, van Putten M, Movig KL, IJzerman MJ., Single dose of fluoxetine increases muscle activation in chronic stroke patients. Clin Neuropharmacol. 2009; 32: 1-5.
34. Flaster M, Sharma A, Rao M., Poststroke depression: a review emphasizing the role of prophylactic treatment and synergy with treatment for motor recovery. Top Stroke Rehabil. 2013; 20: 139-150.
35. Karaiskos D, Tzavellas E, Spengos K, Vassilopoulou S, Paparrigopoulos T., Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety and fatigue. J Neuropsychiatry Clin Neurosci. 2012; 24: 349-353.
36. Robinson RG, Jorge RE, Moser DJ, et al.Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA. 2008; 299: 2391-2400.
37. Shin D, Oh YH, Eom CS, Park SM., Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. J Neurol. 2014; 261: 686-695.
38. Hung CC, Lin CH, Lan TH, Chan CH., The association of selective serotonin reuptake inhibitors use and stroke in geriatric population. Am J Geriatr Psychiatry. 2013; 21: 811-815.
39. Mortensen JK, Larsson H, Johnsen SP, Andersen G., Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke. 2013; 44: 420-426.
40. Hackam DG, Mrkobrada M., Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012; 79: 1862-1865.
41. Lee YC, Lin CH, Lin MS, Lin JW, Chang CH, Lai MS., Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study. J Clin Psychopharmacol. 2013; 33: 782-789.
42. Ried LD, Jia H, Feng H, et al.Selective serotonin reuptake inhibitor treatment and depression are associated with poststroke mortality. Ann Pharmacother. 2011; 45: 888-897.
43. Douglas I, Smeeth L, Irvine D., The use of antidepressants and the risk of haemorrhagic stroke: a nested case control study. Br J Clin Pharmacol. 2011; 71: 116-120.
44. Marquez-Romero JM, Arauz A, Ruiz-Sandoval JL, et al.Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials. 2013; 19: 77.